IL-33 drives the antitumour effects of dendritic cells via upregulating CYLD expression in pulmonary adenocarcinoma
Source abstract
Abstract
Lung adenocarcinoma is one of the leading causes of cancer-related death worldwide. Low expression of Interleukin-33 (IL-33) was reported to be associated with the progression of pulmonary adenocarcinoma. However, the IL-33-mediated immunoregulation in pulmonary adenocarcinoma remains unclear. In this study, we found that IL-33 treatment evidently repressed tumour growth, induced CD4+ T cells infiltration and IL-17 expression in pulmonary adenocarcinoma. Notably, IL-33 treatment increased the number of Dendritic Cells (DCs) in pulmonary adenocarcinoma. More importantly, IL-33 induced maturation and regulated the function of DCs by increasing expression of DCs mature markers (CD40 and CD80, CD86) DCs-function-related gene including antigen presentation genes (HLA-DMA, HLA-DMB and CD74) and cytokines (IL-1β, IL-6 and TNF). Mechanistic studies demonstrated that IL-33 treatment induced DCs maturation by upregulating CYLD expression in DCs. In addition, CYLD played an important role in DCs-induced T cell proliferation and IL-17 secretion. In conclusion, our study demonstrated that IL-33 mediated immunoregulation in pulmonary adenocarcinoma by improving DC-induced T cell proliferation by upregulating CYLD expression.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: IL-33, ST2, and ILC Pathways · Immune Cell Function and Interaction · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Thoracic Surgery, Fujian Provincial Hospital, Provincial Clinical College of Fujian Medical University
Department of thoracic surgery, Yunnan Cancer Hospital, the Third Affiliated Hospital of Kunming Medical University
Department of traditional Chinese medicine, Fujian Province Hospital, School of clinical medicine, Fujian Medical University
Funding
Science and Technology Project of Fujian · The National Natural Science Fund
References (43)
Show source-provided references
1. 10.1126/scitranslmed.aad606610.1126/scitranslmed.aad6066 ↗
2. 10.1158/0008-5472.CAN-17-130710.1158/0008-5472.CAN-17-1307 ↗
3. 10.1158/2326-6066.CIR-17-021810.1158/2326-6066.CIR-17-0218 ↗
4. 10.1073/pnas.180361311510.1073/pnas.1803613115 ↗
5. 10.3389/fimmu.2018.0096210.3389/fimmu.2018.00962 ↗
6. 10.3389/fimmu.2018.0200410.3389/fimmu.2018.02004 ↗
7. 10.1111/all.1365610.1111/all.13656 ↗
8. 10.1080/2162402X.2015.106377210.1080/2162402X.2015.1063772 ↗
9. 10.1158/0008-5472.CAN-16-160210.1158/0008-5472.CAN-16-1602 ↗
10. 10.1016/j.canlet.2013.03.00210.1016/j.canlet.2013.03.002 ↗
11. Gao X, Wang X, Yang Q, et al. Tumoural expression of IL-33 inhibits tumour growth and modifies the tumour microenvironment through CD8+ T and NK cells. JI. 2015;194:438–445.
12. Kim J, Kim W, Moon UJ, et al. Intratumourally establishing type 2 innate lymphoid cells blocks tumour growth. JI. 2016;196:2410–2423.
13. 10.1080/2162402X.2017.131742010.1080/2162402X.2017.1317420 ↗
14. 10.4049/jimmunol.150139910.4049/jimmunol.1501399 ↗
15. 10.18632/oncotarget.2102210.18632/oncotarget.21022 ↗
16. Yang M, Feng Y, Yue C, et al. Lower expression level of IL-33 is associated with poor prognosis of pulmonary adenocarcinoma. PLoS One. 2018;13:e0193428.10.1371/journal.pone.0193428 ↗
17. 10.1038/s41419-018-0889-y10.1038/s41419-018-0889-y ↗
18. 10.1038/srep4539510.1038/srep45395 ↗
19. 10.1183/09031936.06.0011420510.1183/09031936.06.00114205 ↗
20. 10.1038/s41423-018-0166-010.1038/s41423-018-0166-0 ↗
21. 10.1038/nature1442410.1038/nature14424 ↗
22. 10.1158/2326-6066.CIR-17-011710.1158/2326-6066.CIR-17-0117 ↗
23. 10.1038/ni.270310.1038/ni.2703 ↗
24. 10.1038/cr.2017.3410.1038/cr.2017.34 ↗
25. 10.1002/ijc.2542910.1002/ijc.25429 ↗
26. 10.1158/2326-6066.CIR-17-047910.1158/2326-6066.CIR-17-0479 ↗
27. Tran Janco JM, Lamichhane P, Karyampudi L, et al. Tumour-infiltrating dendritic cells in cancer pathogenesis. JI. 2015;194:2985–2991.
28. 10.1186/s13046-015-0126-910.1186/s13046-015-0126-9 ↗
29. 10.3389/fimmu.2018.0178710.3389/fimmu.2018.01787 ↗
30. 10.18632/oncotarget.2506110.18632/oncotarget.25061 ↗
31. 10.1016/j.ccell.2017.04.00310.1016/j.ccell.2017.04.003 ↗
32. 10.1038/s41598-018-30259-210.1038/s41598-018-30259-2 ↗
33. 10.1016/j.cyto.2017.07.02210.1016/j.cyto.2017.07.022 ↗
34. 10.1038/cddis.2011.8210.1038/cddis.2011.82 ↗
35. 10.1093/carcin/bgl08110.1093/carcin/bgl081 ↗
36. 10.1038/leu.2011.35710.1038/leu.2011.357 ↗
37. 10.7150/thno.1084410.7150/thno.10844 ↗
38. 10.1093/carcin/bgt33510.1093/carcin/bgt335 ↗
39. 10.1053/j.gastro.2018.10.02310.1053/j.gastro.2018.10.023 ↗
40. 10.1016/j.immuni.2007.07.01110.1016/j.immuni.2007.07.011 ↗
41. Wex K, Schmid U, Just S, et al. Receptor-interacting protein kinase-2 inhibition by CYLD impairs antibacterial immune responses in macrophages. Front in Immunol. 2015;6:650.
42. 10.1016/j.celrep.2016.05.03210.1016/j.celrep.2016.05.032 ↗
43. 10.1182/blood-2008-08-17548910.1182/blood-2008-08-175489 ↗